MY ACCOUNT | NEWSLETTER |

Benign ureteral obstruction in cats


Limited information is available regarding the outcome of medical management (MM) of benign ureteral obstruction in cats (BUO). The objective of the authors was to describe clinical characteristics and outcome of MM of BUO.

Researchers reviewed medical records of cats diagnosed with BUO between 2010 and 2021 that received >72 hours of medical management. The team analyzed clinical data, treatment and outcome. The outcome was classified as success, partial success, or failure based on ultrasound findings. Factors associated with outcome were assessed.

Seventy-two cats with 103 obstructed kidneys were enrolled in the study.

The causes of obstruction were uroliths in 73% (75/103), strictures in 13.5% (14/103) and pyonephrosis in 13.5% (14/103) of affected kidneys.

Median serum creatinine concentration at presentation was 4.01 mg/dL (range, 1.30-21.3 mg/dL). Outcome after MM was considered a success in 30% (31/103), partial success in 13% (13/103), and failure in 57% (59/103) of kidneys.

Success was reported in 23% (17/75) of kidneys with uroliths, 50% (7/14) with pyonephrosis, and 50% (7/14) with strictures. The median time to a successful outcome was 16 days (range, 3-115 days). Distal and smaller uroliths (median length, 1.85 mm) were significantly associated with success (P = .05 and P = .01, respectively).

Median survival times were 1188 days (range, 60-1700 days), 518 days (range, 7-1812 days), and 234 days (range, 4-3494 days) for success, partial success, and failure, respectively.

In conclusion, the study showed a higher success rate for MM of BUO than previously reported. Smaller distal uroliths (<1-2 mm) were more likely to pass.

Isabelle Merindol, et al. “Benign ureteral obstruction in cats: Outcome with medical management.” J Vet Intern Med. 2023 Apr 19. doi: 10.1111/jvim.16709.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats

Like0
Dislike0

Additive manufacturing to veterinary practice: Recovery of bony defects after the osteosarcoma resection in canines

Like0
Dislike0

Antimicrobial drug use in poultry

Like0
Dislike0

New hope and compassionate care for animal patients in pain

Like0
Dislike0

Neogen® Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top